Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group
IntroductionChemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications....
Saved in:
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-01-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2024.1441056/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850203525569576960 |
|---|---|
| author | Koichi Yasuda Naomi Kiyota Kazuto Matsuura Satoshi Saito Yoshitaka Honma Yoshinori Imamura Kaoru Tanaka Sadamoto Zenda Takuma Onoe Takeshi Kodaira Satoshi Kobayashi Hidefumi Aoyama Nobuhiro Hanai Akihiro Homma |
| author_facet | Koichi Yasuda Naomi Kiyota Kazuto Matsuura Satoshi Saito Yoshitaka Honma Yoshinori Imamura Kaoru Tanaka Sadamoto Zenda Takuma Onoe Takeshi Kodaira Satoshi Kobayashi Hidefumi Aoyama Nobuhiro Hanai Akihiro Homma |
| author_sort | Koichi Yasuda |
| collection | DOAJ |
| description | IntroductionChemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications.MethodsIn April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions.ResultsThe major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65–74 years with PS 0–1 and 65–74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50.DiscussionIn Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients. |
| format | Article |
| id | doaj-art-02fa4b9ca47f4fe896aad50afb573d36 |
| institution | OA Journals |
| issn | 2234-943X |
| language | English |
| publishDate | 2025-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj-art-02fa4b9ca47f4fe896aad50afb573d362025-08-20T02:11:29ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2025-01-011410.3389/fonc.2024.14410561441056Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study groupKoichi Yasuda0Naomi Kiyota1Kazuto Matsuura2Satoshi Saito3Yoshitaka Honma4Yoshinori Imamura5Kaoru Tanaka6Sadamoto Zenda7Takuma Onoe8Takeshi Kodaira9Satoshi Kobayashi10Hidefumi Aoyama11Nobuhiro Hanai12Akihiro Homma13Department of Radiation Oncology, Hokkaido University Hospital, Sapporo, JapanDepartment of Medical Oncology and Hematology, Cancer Center, Kobe University Hospital, Kobe, JapanDepartment of Head and Neck Surgery, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Radiation Oncology, Saitama Medical University International Medical Center, Hidaka, JapanDepartment of Head and Neck, Esophageal Medical Oncology, National Cancer Center Hospital, Tokyo, JapanDepartment of Medical Oncology and Hematology, Kobe University Hospital, Kobe, JapanDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, JapanDepartment of Radiation Oncology and Particle Therapy, National Cancer Center Hospital East, Kashiwa, JapanDivision of Medical Oncology, Hyogo Cancer Center, Akashi, Japan0Department of Radiation Oncology, Aichi Cancer Center Hospital, Aichi, Japan1Department of Gastroenterology, Kanagawa Cancer Center, Yokohama, Japan2Department of Radiation Oncology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan3Department of Head and Neck Surgery, Aichi Cancer Center Hospital, Nagoya, Japan4Department of Otolaryngology-Head & Neck Surgery, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, JapanIntroductionChemoradiation therapy (CRT) with concurrent high-dose cisplatin (CDDP) is one of the standard treatment options for locally advanced head and neck cancer. Since the indications specific to the older population have not been reported, we conducted a multicenter survey on the indications.MethodsIn April and May 2023, a questionnaire survey was emailed to all institutions belonging to the JCOG-HNCSG, consisting of 37 institutions.ResultsThe major factors influencing the indications for high-dose CDDP were renal function and performance status (PS). The majority agreed that the treatment is administered to patients aged 65–74 years with PS 0–1 and 65–74 years with eGFR ≥60 (ml/ min/1.73m2), and not in patients aged ≥75 years with PS 2, ≥80 years with PS 1, and ≥65 years with eGFR <60. Regarding weekly CDDP, the majority agreed that the treatment is not conducted in patients aged ≥75 years with PS 2, ≥65 years with eGFR <40, and ≥70 years with eGFR <50.DiscussionIn Japan, where CRT is actively performed even among older people, a survey was conducted to determine its indications. Renal function and PS were considered important, and comorbidities, such as heart failure, were considered while determining the indication. These results will help define the eligibility criteria for prospective studies on CRT in older patients.https://www.frontiersin.org/articles/10.3389/fonc.2024.1441056/fullolder patientshead and neck cancerchemoradiotherapyradiotherapycisplatin |
| spellingShingle | Koichi Yasuda Naomi Kiyota Kazuto Matsuura Satoshi Saito Yoshitaka Honma Yoshinori Imamura Kaoru Tanaka Sadamoto Zenda Takuma Onoe Takeshi Kodaira Satoshi Kobayashi Hidefumi Aoyama Nobuhiro Hanai Akihiro Homma Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group Frontiers in Oncology older patients head and neck cancer chemoradiotherapy radiotherapy cisplatin |
| title | Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group |
| title_full | Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group |
| title_fullStr | Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group |
| title_full_unstemmed | Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group |
| title_short | Indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in Japan: a questionnaire survey in the JCOG head and neck cancer study group |
| title_sort | indications for chemoradiotherapy in older patients with locally advanced head and neck cancer in japan a questionnaire survey in the jcog head and neck cancer study group |
| topic | older patients head and neck cancer chemoradiotherapy radiotherapy cisplatin |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2024.1441056/full |
| work_keys_str_mv | AT koichiyasuda indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT naomikiyota indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT kazutomatsuura indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT satoshisaito indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT yoshitakahonma indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT yoshinoriimamura indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT kaorutanaka indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT sadamotozenda indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT takumaonoe indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT takeshikodaira indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT satoshikobayashi indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT hidefumiaoyama indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT nobuhirohanai indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup AT akihirohomma indicationsforchemoradiotherapyinolderpatientswithlocallyadvancedheadandneckcancerinjapanaquestionnairesurveyinthejcogheadandneckcancerstudygroup |